Literature DB >> 1574183

Major and minor birth malformations and antiepileptic drugs.

S Koch1, G Lösche, E Jager-Romän, S Jakob, D Rating, A Deichl, H Helge.   

Abstract

In a study of infants of parents with epilepsy, malformations were twice as prevalent in these children as in controls. Children of mothers with epilepsy had more minor anomalies than those of fathers with epilepsy or controls. At 1 year of age, a greater number of minor anomalies was seen in children of mothers with epilepsy who had received treatment with antiepileptic drugs (AEDs) during pregnancy, whereas at 4 years, no difference was observed. Type of epilepsy, seizures during pregnancy, plasma levels of phenytoin or phenobarbital in the medium range, and fetal intrauterine growth did not correlate with the number of minor anomalies. We suggest that the special genetic background that predisposes to epilepsy also renders the fetus more vulnerable to major and minor anomalies. Although linkage between epilepsy and malformation is stronger than between AEDs and malformations, valproate, phenytoin, and phenobarbital show specific teratogenic effects. In addition, all AEDs unspecifically increase the number of minor anomalies. Under therapeutic conditions, valproate may be regarded as considerably teratogenic and all other observed AEDs as weakly teratogenic.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1574183

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

Review 1.  Teenagers with epilepsy.

Authors:  R E Appleton; B G Neville
Journal:  Arch Dis Child       Date:  1999-07       Impact factor: 3.791

2.  Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.

Authors:  J Morrow; A Russell; E Guthrie; L Parsons; I Robertson; R Waddell; B Irwin; R C McGivern; P J Morrison; J Craig
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09-12       Impact factor: 10.154

Review 3.  Advances in Epidemiological Methods and Utilisation of Large Databases: A Methodological Review of Observational Studies on Central Nervous System Drug Use in Pregnancy and Central Nervous System Outcomes in Children.

Authors:  Zixuan Wang; Phoebe W H Ho; Michael T H Choy; Ian C K Wong; Ruth Brauer; Kenneth K C Man
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

Review 4.  Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.

Authors:  Jennifer Weston; Rebecca Bromley; Cerian F Jackson; Naghme Adab; Jill Clayton-Smith; Janette Greenhalgh; Juliet Hounsome; Andrew J McKay; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2016-11-07

Review 5.  Do lamotrigine and levetiracetam solve the problem of using sodium valproate in women with epilepsy?

Authors:  John J Craig
Journal:  Obstet Med       Date:  2012-02-20

Review 6.  Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts.

Authors:  Kimford Meador; Matthew W Reynolds; Sheila Crean; Kyle Fahrbach; Corey Probst
Journal:  Epilepsy Res       Date:  2008-06-18       Impact factor: 3.045

Review 7.  Management of epilepsy during pregnancy.

Authors:  Dina Battino; Torbjörn Tomson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Malformation rates in children of women with untreated epilepsy: a meta-analysis.

Authors:  Shawn Fried; Eran Kozer; Irena Nulman; Thomas R Einarson; Gideon Koren
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Anticonvulsant Use in the Treatment of Bipolar Disorder: A Primer for Primary Care Physicians.

Authors:  Raphael J. Leo; Rajesh Narendran
Journal:  Prim Care Companion J Clin Psychiatry       Date:  1999-06

10.  More questions than answers! Clinical dilemmas in psychopharmacology in pregnancy and lactation.

Authors:  Geetha Desai; Girish N Babu; Ravi P Rajkumar; Prabha S Chandra
Journal:  Indian J Psychiatry       Date:  2009-01       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.